A [substantial part of drug use]{.smallcaps}is hidden from the observation of classical epidemiological methods (e.g., surveys). Information on the number and characteristics of people entering treatment for their drug use provides insight into general trends in problem drug use and offers a perspective on the organization and uptake of treatment.

The Treatment Demand Indicator (TDI), one of the five key epidemiological indicators[^1^](#fn1){ref-type="fn"} of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA),[^2^](#fn2){ref-type="fn"} has been implemented to obtain comparable and reliable information on the number, characteristics, and substance use patterns of drug users entering drug treatment in the European countries. In many European countries, treatment data are the primary source of information about high-risk drug use at the national level, and the client population captured by the TDI constitutes a substantial sample of all people with drug problems in the community. The analysis of changes in the profile and in the number of drug users reported through the TDI helps to identify trends in problem drug use. In combination with information on coverage of the TDI within the national treatment system ([@B9]), the collected data also offer a perspective on availability, accessibility, and organization of treatment services, which can be useful in the evaluation and planning of drug services.

Information collected through the TDI in 30 countries is largely used to inform the yearly *European Drug Report* ([@B11]), the *Statistical Bulletin* ([@B13]), and other EMCDDA thematic publications.

The history of the TDI starts more than 20 years ago, when a first harmonized data collection form was defined at the European Union (EU) level. The first core data set was based on the experience of existing national data collection systems in drug treatment in Europe. In 1994, the Pompidou Group at the Council of Europe,[^3^](#fn3){ref-type="fn"} the first European intergovernmental body for collaboration on drug issues, defined a common protocol for collecting data on people entering drug treatment at the city level ([@B15]; [@B25]). Initially, the project covered six cities (Amsterdam, Dublin, Hamburg, London, Paris, and Stockholm) and then developed into a pan-European "multicity" project. The "Pompidou Group protocol" was implemented in several western and southern European countries and from 1993 onward also in central and eastern European cities under a cooperation program between the Pompidou Group and the United Nations Office on Drugs and Crime (UNODC). A revision of the Pompidou Group protocol in the late 1990s led to the publication of the EMCDDA/Pompidou Group TDI protocol 2.0 ([@B24]).

In 1995, the EMCDDA assumed responsibility for collecting treatment demand data in the member states of the EU. The EMCDDA is a decentralized agency of the European Commission, established in 1993 and operational since 1995 ([@B5]), with the aim to provide objective, reliable, and comparable information on drugs and drug addiction in the countries of the EU. The organization's role is to provide the EU and its member states with a factual overview of European drug problems and a common information framework to support the drugs debate.

To achieve its mission, the EMCDDA coordinates and relies on a network of 30 national monitoring centers, the Reitox national focal points. Reitox, "Réseau Européen d'Information sur les Drogues et les Toxicomanies," is the European information network on drugs and drug addiction ([@B14]). This network is made up of formal national drug observatories in each of the 30 countries reporting to the EMCDDA (the 28 EU member states, the candidate country Turkey, and Norway) and provides annually to the EMCDDA the most up-to-date standardized epidemiological and qualitative information on the drug situation, interventions, and policies at the member-state level. The EMCDDA publishes on a wide range of drug-related topics, across epidemiology, interventions, laws, and policies ([@B14]; [@B19]).

In 2001, the EMCDDA Management Board ([@B7]) and the Council of the European Union ([@B3]) formally adopted the TDI as an EU-wide standard, together with four other key epidemiological indicators. The formal endorsement of the indicators supported their implementation at the national level.

In 2012, the TDI protocol was revised, with the publication of the TDI Protocol version 3.0 ([@B8]). The revised TDI protocol reflected changes in patterns of drug use and client profiles (i.e., diversified patterns and clients), in the drug treatment systems (i.e., expansion and diversification of treatment), and in methodological and technical developments in data monitoring (i.e., development of an information technology system).

The TDI protocol 3.0 is currently available online in 12 languages,[^4^](#fn4){ref-type="fn"} and it is used as a data collection tool in drug treatment in the 28 countries of the EU,[^5^](#fn5){ref-type="fn"} Norway, and Turkey, as well as in some countries of the Balkan region, the Mediterranean area, North and West Africa, and South America.

This article provides an overview of the TDI and its implementation in the European countries in the last 10 years by describing the latest available data and discussing the methodological aspects, limitations, and future perspectives for the development of the indicator.

Method
======

The TDI provides a uniform structure for reporting data on clients seeking care in drug treatment facilities at, or close to, their point of entry into treatment for problems with one or more drugs. It is designed to satisfy monitoring requirements at the European level. In addition, it is envisaged that each country or member state supplements the common core data set with additional variables to inform local or national data collection needs.

Data are collected on two groups of clients: those entering drug treatment for the first time during the reporting year ("clients entering treatment") and, among them, those entering treatment for the first time in their life ("first-time treatment entrants"). The recommended period for data collection indicated in the protocol is from January 1 to December 31.

To ensure comparability, specific indications are provided for inclusion and exclusion of clients in the TDI register according to their treatment episode (start/end of treatment and treatment episode) ([@B8]). For each presenting client, a core data set of 24 items is reported anonymously concerning sociodemographic characteristics of the client, patterns of drug use, and use of services ([Table 1](#T1){ref-type="table"}).

###### 

Items list of the Treatment Demand Indicator protocol 3.0[*^a^*](#tblfn2){ref-type="table-fn"}
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  No.                                                                                         Item                                              Answers
  ------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------------
  1                                                                                           Treatment center type                             • Outpatient treatment centers/programs
  • Inpatient treatment centers/programs                                                                                                        
  • Treatment units in prison/programs                                                                                                          
  • General practitioners/programs                                                                                                              
  • Low threshold agencies/programs                                                                                                             
  • Other (please specify which type of treatment)                                                                                              
  • Not known                                                                                                                                   
  2                                                                                           Year of treatment                                 Year\_\_\_\_\_\_
  3                                                                                           Ever previously treated (First in the year)       • Never previously treated
  • Previously treated                                                                                                                          
  • Not known                                                                                                                                   
  4                                                                                           Source of referral                                • Court/probation/police
  • General practitioner                                                                                                                        
  • Other drug treatment center                                                                                                                 
  • Other health, medical, or social service                                                                                                    
  • Educational services                                                                                                                        
  • Self-referral, referral from family, friends, etc./no other agency/institution involved                                                     
  • Others                                                                                                                                      
  • Not known                                                                                                                                   
  5                                                                                           Sex                                               • Male
  • Female                                                                                                                                      
  • Not known                                                                                                                                   
  6                                                                                           Age at treatment start                            Years\_\_\_\_\_
  Not known                                                                                                                                     
  7                                                                                           Living status (with whom)                         • Alone
  • With the family of origin (parents, etc.)                                                                                                   
  • With partner/children                                                                                                                       
  • With friends or other people (with no family relation)                                                                                      
  • In detention                                                                                                                                
  • In institutions/shelters (not detention)                                                                                                    
  • Others                                                                                                                                      
  • Not known                                                                                                                                   
  8                                                                                           Drug clients with children                        • Not having children
  • Having children                                                                                                                             
  • Not living with children                                                                                                                    
  • Living with children                                                                                                                        
  • Not known                                                                                                                                   
  9                                                                                           Living status (where)                             • Stable accommodation
  • Unstable accommodation and/or homeless                                                                                                      
  • In detention                                                                                                                                
  • Others                                                                                                                                      
  • Not known                                                                                                                                   
  10                                                                                          Labor status                                      • Occasionally employed
  • Regularly employed                                                                                                                          
  • Student                                                                                                                                     
  • Unemployed/discouraged                                                                                                                      
  • Receiving social benefits/pensioners/house-makers/disabled                                                                                  
  • Others                                                                                                                                      
  • Not known                                                                                                                                   
  11                                                                                          Highest educational level completed               • Never went to school/never completed primary school (= ISCED 0)
  • Primary level of education (= ISCED 1)                                                                                                      
  • Secondary level of education (= ISCED 2 and ISCED 3)                                                                                        
  • Higher education (= ISCED 4 to 6)                                                                                                           
  • Not known                                                                                                                                   
  12                                                                                          Primary drug                                      Opioids (total)
    Heroin                                                                                                                                      
    Methadone misused                                                                                                                           
    Buprenorphine misused                                                                                                                       
    Fentanyl illicit/misused                                                                                                                    
    Other opioids (please specify)                                                                                                              
  Cocaine (total)                                                                                                                               
    Powder cocaine HCl                                                                                                                          
    Crack cocaine                                                                                                                               
    Other (please specify)                                                                                                                      
  Stimulants other than cocaine (total)                                                                                                         
    Amphetamines                                                                                                                                
    Methamphetamines                                                                                                                            
    MDMA and derivatives                                                                                                                        
    Synthetic cathinones                                                                                                                        
    Other stimulants (please specify)                                                                                                           
  Hypnotics and sedatives (total)                                                                                                               
    Barbiturates misused                                                                                                                        
    Benzodiazepines misused                                                                                                                     
    GHB/GBL                                                                                                                                     
    Other hypnotics and sedatives misused (please specify)                                                                                      
  Hallucinogens (total)                                                                                                                         
    LSD                                                                                                                                         
    Ketamine                                                                                                                                    
    Other hallucinogens (please specify)                                                                                                        
  Volatile inhalants                                                                                                                            
  Cannabis (total)                                                                                                                              
  Other substances (total) (please specify which substances) Not known                                                                          
  13                                                                                          Usual route of administration                     • Inject
  • Smoke/inhale                                                                                                                                
  • Eat/drink                                                                                                                                   
  • Sniff                                                                                                                                       
  • Others                                                                                                                                      
  • Not known                                                                                                                                   
  14                                                                                          Frequency of use of primary drug                  • Daily
  • 4--6 days per week                                                                                                                          
  • 2--3 days per week                                                                                                                          
  • Once a week or less                                                                                                                         
  • Not used in the last 30 days                                                                                                                
  • Not known                                                                                                                                   
  15                                                                                          Age at first use of primary drug                  Years\_\_\_\_
  Not known                                                                                                                                     
  16                                                                                          Secondary drug                                    Opioids (total)
    Heroin                                                                                                                                      
    Methadone misused                                                                                                                           
    Buprenorphine misused                                                                                                                       
    Fentanyl illicit/misused                                                                                                                    
    Other opioids (please specify)                                                                                                              
  Cocaine (total)                                                                                                                               
    Powder cocaine HCl                                                                                                                          
    Crack cocaine                                                                                                                               
    Other (please specify)                                                                                                                      
  Stimulants other than cocaine (total)                                                                                                         
    Amphetamines                                                                                                                                
    Methamphetamines                                                                                                                            
    MDMA and derivatives                                                                                                                        
    Synthetic cathinones                                                                                                                        
    Other stimulants (please specify)                                                                                                           
  Hypnotics and sedatives (total)                                                                                                               
    Barbiturates misused                                                                                                                        
    Benzodiazepines misused                                                                                                                     
    GHB/GBL                                                                                                                                     
    Other hypnotics and sedatives misused (please specify)                                                                                      
  Hallucinogens (total)                                                                                                                         
    LSD                                                                                                                                         
    Ketamine                                                                                                                                    
    Other hallucinogens (please specify)                                                                                                        
  Volatile inhalants                                                                                                                            
  Cannabis (total)                                                                                                                              
  Alcohol as secondary drug (total)                                                                                                             
  Other substances (total) (please specify which substances)                                                                                    
  Not known                                                                                                                                     
  17                                                                                          Polydrug use problem                              Yes
  No                                                                                                                                            
  Not known                                                                                                                                     
  18                                                                                          Opioid substitution treatment                     Never been in opioid substitution treatment
  Ever been in opioid substitution treatment Not known                                                                                          
  19                                                                                          Age at opioid substitution treatment (in years)   Age at first opioid substitution treatment: /\_\_\_\_\_\_/Not known
  20                                                                                          Ever injected or currently injecting any drug     Never injected
  Ever injected                                                                                                                                 
  Injected, but not in the last 12 months                                                                                                       
  Injected in the last 12 months, but not in the last 30 days                                                                                   
  Currently injecting (in the last 30 days)                                                                                                     
  Don't want to answer                                                                                                                          
  Not known                                                                                                                                     
  21                                                                                          Age at first injection                            Years\_\_\_\_\_\_\_\_\_\_\_\_
  Not known                                                                                                                                     
  22                                                                                          HIV testing                                       Never tested
  Ever tested                                                                                                                                   
  Tested, but not in the last 12 months                                                                                                         
  Tested in the last 12 months                                                                                                                  
  Don't want to answer                                                                                                                          
  Not known                                                                                                                                     
  23                                                                                          HCV testing                                       Never tested
  Ever tested                                                                                                                                   
  Tested, but not in the last 12 months                                                                                                         
  Tested in the last 12 months                                                                                                                  
  Don't want to answer                                                                                                                          
  Not known                                                                                                                                     
  24                                                                                          Needle/syringe sharing                            Never shared a needle or syringe
  Ever shared a needle or syringe                                                                                                               
  Shared, but not in the last 12 months                                                                                                         
  Shared in the last 12 months, but not in the last 30 days                                                                                     
  Currently shared (in the last 30 days)                                                                                                        
  Don't want to answer                                                                                                                          
  Not known                                                                                                                                     

*Notes:* ISCED = International Standard Classification of Education; HCl = hydrochloric acid; MDMA = 3,4-methylenedioxymethamphetamine (Ecstasy); GHB/GBL = γ-hydroxybutyric acid/γ-butyrolactone ("club drugs"); LSD = lysergic acid diethylamide; HCV = hepatitis C virus.

See page 43 of the Treatment Demand Indicator protocol ([@B8]).

TDI data are collected in the centers that provide specialized drug treatment, which is defined as "any activity which directly targets people who have problems with their drug use and aims to achieve defined objectives with regard to the alleviation and/or elimination of these problems, provided by experienced or accredited professionals, in the framework of recognized medical, psychological or social assistance practice." Five types of treatment centers can be included in the data collection: (a) outpatient treatment centers, (b) inpatient treatment centers, (c) low-threshold agencies, (d) treatment units in prison, and (e) general practices.

The TDI collects data by the primary drug, which is defined as the drug that causes the client the most problems at the start of treatment. This is usually based on the request made by the clients and/or on the diagnosis made by a therapist, commonly using standard clinical instruments (e.g., the *International Classification of Diseases, 10th Revision; Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition;* and Addiction Severity Index). Up to four additional drugs that create problems for the clients can be recorded in addition to the primary drugs, and they are defined as secondary drugs.[^6^](#fn6){ref-type="fn"}

The broad drug categories included in the TDI protocol are opioids, cocaine, stimulants other than cocaine, cannabis, hypnotics and sedatives, hallucinogens, volatile substances/inhalants, and other substances (not included in the categories above). Each category is broken down into specific substances. According to the EMCDDA regulation ([@B5]), only illicit drugs and licit drugs in the context of polydrug use are subject to EMCDDA monitoring. Therefore, the TDI does not collect data on tobacco, and it collects data on alcohol only if it is used together with an illicit drug.

Data are collected at the level of the treatment centers, collated at the national level, and transmitted to the Reitox national focal points ([@B14]), which send aggregated data to the EMCDDA's online database Fonte once per year. This process can result in a 1.5-year delay between the year when data are collected at the local level and the year when the data are reported to the EMCDDA. After submission, data go through a process of quality assurance lasting several months. During this period, data are checked for several parameters (e.g., internal and temporal consistencies, internal and external validities, thorough cross-checking with other data and information sources), and a regular dialogue with experts from the 30 EU countries allows the EMCDDA to ensure data quality.

A number of ethical issues should be considered when TDI data are collected. The main ethical principles described in the TDI protocol concern the purpose of data collection and data protection. Data should be collected with the purpose of obtaining basic information on the epidemiological situation and of supporting evidence-based health interventions. For every level of information (e.g., clinical, regional, national, and institutional), national and international rules of confidentiality and data protection must be considered, as well as the rights of clients, staff, and treatment centers ([@B8]).

Results
=======

Data 2015
---------

In 2015 (or the most recent year available before 2015), 29[^7^](#fn7){ref-type="fn"} European countries (EU-29) reported data on 467,811 clients entering drug treatment from 6,846 drug treatment units; 37% of these were first-time treatment entrants (*N* = 172,303). Five large EU countries (France, Germany, Italy, Spain, and the United Kingdom)---where 53% of the European adult population live---reported more than 70% of drug clients entering treatment in Europe ([Table 2](#T2){ref-type="table"}).

###### 

First-time treatment entrants and clients entering treatment and social characteristics in 2015 or most recent year available
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                                                          New clients entering drug treatment                                                                         
  ---------------- ---------- ------------- ------------- ------------------------------------- ---------- ------------ --------- ------------ --------- ------------ --------
  Austria          2015       1,536         4,400         3                                     30.4       487          40%       84           6%        91           6%
  Belgium          2015       4,415         12,794        3                                     33.0       962          23%       1,525        38%       284          6%
  Bulgaria         2014       560           2,131         4                                     31.4       100          39%       101          40%       22           9%
  Croatia          2015       848           7,537         5                                     23.0       277          33%       305          37%       84           10%
  Cyprus           2015       436           798           8                                     29.3       144          34%       154          38%       27           6%
  Czech Republic   2014       4,743         10,108        2                                     29.5       2,660        64%       2,108        54%       1,310        33%
  Denmark          2014       2,756         6,275         3                                     29.4       1,223        46%       329          13%       111          4%
  Estonia          2015       63            282           3                                     33.1       34           55%       35           57%       3            5%
  Finland          2015       277           656           2                                     30.0       145          53%       153          58%       19           7%
  France           2015       17,789        62,213        4                                     32.0       3,113        18%       623          4%        1,813        11%
  Germany          2015       23,054        72,102        4                                     31.5       8,591        35%       6,214        26%       1,298        5%
  Greece           2015       1,586         4,087         6                                     34.5       796          51%       375          25%       168          11%
  Hungary          2015       2,956         4,308         7                                     29.0       597          20%       1,370        48%       74           3%
  Ireland          2015       3,742         9,489         3                                     30.6       2,099        57%       559          20%       279          8%
  Italy            2015       20,731        47,213        7                                     36.7       5,598        38%       1,282        8%        924          6%
  Latvia           2015       391           751           5                                     30.6       2            2%        34           10%       2            1%
  Lithuania        2015       395           2,549         4                                     33.3       79           20%       128          32%       28           7%
  Luxembourg       2015       24            290           3                                     35.6       7            29%       12           75%       6            25%
  Malta            2015       276           1,829         4                                     25.4       62           26%       47           21%       4            2%
  Netherlands      2015       6,529         10,987        4                                     33.0       1,548        36%       1,313        35%       96           2%
  Norway           2015       --            5,908         2                                     34.6       --           --        --           --        --           --
  Poland           2015       4,296         9,013         5                                     26.2       1,224        29%       2,126        50%       327          8%
  Portugal         2015       2,024         3,389         6                                     36.2       806          43%       731          39%       157          9%
  Romania          2015       2,076         3,240         6                                     28.0       610          30%       174          9%        144          7%
  Slovakia         2015       1,289         2,720         5                                     29.5       684          53%       524          42%       187          15%
  Slovenia         2015       88            316           3                                     33.9       33           38%       42           48%       16           18%
  Spain            2014       23,656        47,308        5                                     34.2       11,306       49%       13,313       57%       421          2%
  Turkey           2015       5,377         10,884        19                                    26.8       2,888        54%       4,022        75%       1            0%
  United Kingdom   2015       40,390        124,234       3                                     32.9       9,236        31%       3,472        11%       --           --
  **Total**        **2015**   **172,303**   **467,811**   **4**                                 **32.8**   **55,311**   **37%**   **37,683**   **32%**   **11,368**   **7%**

*Notes:* Tx = treatment. Data for Sweden are excluded due to comparability problems with the Treatment Demand Indicator (TDI) protocol 3.0 definitions. No data on first-time treatment entrants are available for Norway. Data from Bulgaria, Czech Republic, Denmark, and Spain refer to 2014 because that was the last year of available data. Data were not available on level of education for 58,580 first-time treatment entrants, labor status for 23,821 clients, and living conditions for 28,193 clients. Data on level of education are not available in the United Kingdom. Data for Sweden are excluded due to comparability problems with the TDI protocol 3.0 definitions. No data on first-time treatment entrants are available for Norway. Data from Bulgaria, the Czech Republic, Denmark, and Spain refer to 2014 because that was the last year of available data.

Eighty percent of first-time treatment entrants were male, with a mean age of 33 years. The male-to-female ratios were 2:1 in the Czech Republic, Finland, and Norway; 19:1 in Turkey; and 8:1 in Cyprus. The mean age at treatment entry ranged from 23 years in Croatia to 37 years in Italy. Thirty-seven percent of the clients were unemployed (compared with 9.4% in the general population); 7% were homeless and/or without a stable accommodation (compared with 5% in "severe housing conditions" in the general population); and 32% of drug clients had not advanced beyond primary education (compared with 10% having lower secondary education among young people in the general population[^8^](#fn8){ref-type="fn"}) ([@B11]).

Looking at patterns of drug use among clients entering treatment in Europe in 2015, the largest group of drug clients entered treatment for problems related to primary use of opioids, mainly heroin (38%), followed by those entering treatment for primary use of cannabis (31%), and those entering treatment for primary use of cocaine (13%), stimulants other than cocaine (mainly amphetamines and methamphetamines) (8%), and other substances (10%), including hypnotics and sedatives, hallucinogens, and volatile substances/inhalants ([Table 3](#T3){ref-type="table"}).

###### 

Number of clients entering drug treatment by country and primary drug in 2015 or most recent year available with known primary drug
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  Country          Year of tx   Opioids       Cocaine      Stimulants other than cocaine   Hypnotics and sedatives   Halluci-nogens   Volatile inhalants   Cannabis      Other substances   Total
  ---------------- ------------ ------------- ------------ ------------------------------- ------------------------- ---------------- -------------------- ------------- ------------------ -------------
  Austria          2015         2,016         258          197                             96                        4                1                    1,063         5                  3,640
  Belgium          2015         3,234         2,207        1,289                           1,077                     37               7                    3,737         110                11,698
  Bulgaria         2014         1,530         29           87                              49                        0                4                    58            47                 1,804
  Croatia          2015         6,124         104          143                             111                       3                1                    967           84                 7,537
  Cyprus           2015         205           80           39                              2                         1                --                   469           1                  797
  Czech Republic   2014         1,720         27           7,038                           64                        7                16                   1,195         23                 10,090
  Denmark          2014         613           260          326                             64                        5                7                    3,338         92                 4,705
  Estonia          2015         263           2            6                               --                        --               1                    10            --                 282
  Finland          2015         339           0            119                             55                        3                1                    136           3                  656
  France           2015         13,744        3,013        549                             987                       307              68                   29,621        752                49,041
  Germany          2015         28,669        5,209        14,646                          1,805                     136              51                   34,108        2,632              87,256
  Greece           2015         2,836         269          31                              115                       9                2                    789           10                 4,061
  Hungary          2015         156           99           717                             154                       225              15                   2,420         522                4,308
  Ireland          2015         4,515         996          147                             1,011                     9                15                   2,681         115                9,489
  Italy            2015         25,144        11,935       193                             216                       43               2                    9,225         455                47,213
  Latvia           2015         402           9            132                             12                        4                15                   175           2                  751
  Lithuania        2015         2,268         15           70                              47                        5                9                    89            46                 2,549
  Luxembourg       2015         163           55           1                               2                         --               1                    67            1                  290
  Malta            2015         1,296         281          25                              1                         2                3                    158           5                  1,771
  Netherlands      2015         1,262         2,675        929                             729                       17               7                    5,202         166                10,987
  Norway           2015         1,005         83           823                             679                       36               2                    1,609         1,671              5,908
  Poland           2015         1,465         189          3,264                           354                       21               30                   2,525         1,165              9,013
  Portugal         2015         1,357         331          13                              25                        1                --                   934           95                 2,756
  Romania          2015         1,057         19           30                              92                        15               33                   1,272         722                3,240
  Slovakia         2015         602           19           1,137                           70                        3                56                   616           --                 2,503
  Slovenia         2015         236           13           6                               14                        0                0                    45            2                  316
  Spain            2014         12,032        17,864       860                             1,192                     82               20                   16,478        398                48,926
  Turkey           2015         8,073         198          308                             65                        33               177                  653           1,377              10,884
  United Kingdom   2015         59,763        16,673       5,844                           3,457                     341              232                  31,129        2,855              120,294
  **Total**        **2015**     **182,089**   **62,912**   **38,963**                      **12,545**                **1,349**        **776**              **150,769**   **13,356**         **462,765**

*Note:* Tx = treatment.

The proportion of clients entering drug treatment for problems related to the primary use of opioids ranged from 4% in Hungary to 93% in Estonia; that of primary cocaine clients varied from 0% in Finland to 37% in Spain; primary cannabis clients ranged from 3% in Bulgaria to 71% in Denmark; and the proportion of clients entering treatment for stimulants other than cocaine ranged from 1% or less in France, Greece, Italy, Luxembourg, Malta, Portugal, and Romania to 70% in the Czech Republic.

New psychoactive substances (NPSs)[^9^](#fn9){ref-type="fn"} ([@B4]) are included in the group of "other substances." These are mainly synthetic cannabinoids and cathinones and represent the main reasons for entering treatment for about 3,000 clients in Europe, or less than 1% of clients entering treatment in 2015, and are mostly reported by Poland, the Netherlands, and the United Kingdom.

When looking at first-time treatment entrants, 45% entered treatment for problems related to primary cannabis use; fewer entered for using opioids (20%), cocaine (15%), and stimulants other than cocaine (10%). The remaining clients entered treatment for primary use of other substances ([Table 4](#T4){ref-type="table"}). In Europe, injecting drug use is most commonly associated with opioids, although in a few countries, the injection of stimulants such as amphetamines or cocaine is a problem. Nineteen percent of clients entering treatment in 2015 injected their primary drug ([@B11]).

###### 

Number of first-time drug treatment entrants by country and primary drug in 2015 or most recent year available (% out of all first-time treatment entrants) with known primary drug
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  Country          Year of tx   Opioids      Cocaine      Stimulants other than cocaine   Hypnotics And sedatives   Halluci-nogens   Volatile inhalants   Cannabis     Other substances   Total
  ---------------- ------------ ------------ ------------ ------------------------------- ------------------------- ---------------- -------------------- ------------ ------------------ -------------
  Austria          2015         351          125          89                              25                        3                0                    711          3                  1,307
  Belgium          2015         411          756          392                             314                       19               3                    2,065        41                 4,001
  Bulgaria         2014         207          21           53                              5                         0                1                    27           7                  321
  Croatia          2015         176          24           30                              41                        1                0                    526          50                 848
  Cyprus           2015         50           36           17                              1                         1                --                   330          --                 435
  Czech Republic   2014         333          12           3,553                           31                        6                7                    776          10                 4,728
  Denmark          2014         124          134          151                             18                        4                4                    1,783        39                 2,257
  Estonia          2015         55           --           2                               --                        --               1                    5                               63
  Finland          2015         106          0            51                              16                        3                1                    99           1                  277
  France           2015         2,378        963          191                             234                       77               13                   11,855       115                15,826
  Germany          2015         3,552        1,494        5,134                           538                       38               14                   15,168       701                26,639
  Greece           2015         834          141          12                              38                        6                2                    539          4                  1,576
  Hungary          2015         46           75           510                             54                        151              8                    1,854        258                2,956
  Ireland          2015         971          513          86                              399                       8                6                    1,693        66                 3,742
  Italy            2015         8,040        6,296        116                             111                       23               --                   5,810        335                20,731
  Latvia           2015         128          7            90                              8                         4                13                   139          2                  391
  Lithuania        2015         261          7            31                              17                        4                4                    47           24                 395
  Luxembourg       2015         6            4            --                              --                        --               --                   14           --                 24
  Malta            2015         66           91           5                               --                        --               --                   67           1                  230
  Netherlands      2015         402          1,357        579                             427                       14               6                    3,625        119                6,529
  Poland           2015         208          83           1,613                           134                       9                15                   1,558        676                4,296
  Portugal         2015         458          239          11                              19                        1                --                   806          52                 1,586
  Romania          2015         360          18           24                              18                        12               18                   1,137        489                2,076
  Slovakia         2015         179          9            541                             19                        1                27                   430          --                 1,206
  Slovenia         2015         37           8            6                               2                         0                0                    34           1                  88
  Spain            2014         2,486        8,234        542                             790                       49               11                   11,386       158                23,656
  Turkey           2015         3,627        79           213                             37                        25               83                   416          897                5,377
  United Kingdom   2015         8,595        6,830        2,755                           1,511                     160              133                  18,345       1,307              39,636
  **Total**        **2015**     **34,447**   **27,556**   **16,797**                      **4,807**                 **619**          **370**              **81,245**   **5,356**          **171,197**

*Notes:* Cocaine includes powder cocaine, crack cocaine, and "other." Data for Norway are for clients entering specialized treatment and are not fully in line with the Treatment Demand Indicator (TDI) protocol 3.0. Data for Sweden are excluded due to comparability problems with the TDI protocol 3.0 definitions. No data on first-time treatment entrants are available for Norway, so data on clients entering drug treatment were included. Data from Bulgaria, the Czech Republic, Denmark, and Spain refer to 2014 because that was the last year of available data. Tx = treatment.

Trends
------

To provide a description of treatment incidence and recent trends in drug treatment demand, the analysis of changes over time in the primary drug of use among treatment clients has focused on first-time treatment entrants.

Over the past two decades, data collected from people entering drug treatment have revealed substantial changes in the prevailing patterns of drug use. Sufficient data to describe trends at the European level are only available since 2006 and only for 23 countries with available data for the period of analysis.

As contextual information, between 2006 and 2015 the number of countries reporting TDI data rose from 27 to 29, and the number of drug treatment clients reporting TDI data increased from 396,349 to 467,811[^10^](#fn10){ref-type="fn"} ([Figure 1](#F1){ref-type="fig"}) ([@B11]).

![Number of data reported through the Treatment Demand Indicator (TDI) from 2006 to 2015: first-time treatment entrants and treatment entrants by year and reporting units. *Notes:* Only countries with at least 9 years of data over the last 10 years were included in the graph. Missing data were interpolated by assigning for the respective country the value for most recent year available. Data reported for 21 countries: Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Malta, Romania, the Netherlands, Slovakia, Slovenia, Spain, Turkey, and United Kingdom. Excluded countries are Belgium, Denmark, Estonia, Lithuania, Luxembourg, Norway, Poland, Portugal, and Sweden. Czech Republic, Malta, and Spain did not report data in 2015; therefore, 2014 data have been used for 2015. Malta did not report data for 2007; therefore, 2006 data have been used for 2007. United Kingdom did not report data for 2012; therefore, 2011 data have been used for 2012.](jsads.2019.s18.139fig1){#F1}

Of first-time treatment entrants between 2006 and 2015, the number of opioid clients decreased from 56,000 (37%) to 33,000 (21%). Between 2014 and 2015, 10 countries reported an increase in the number of opioid (mainly heroin) clients,[^11^](#fn11){ref-type="fn"} and six countries[^12^](#fn12){ref-type="fn"} reported an increase in the proportion of heroin clients out of all first-time treatment entrants. Among opioid clients, those using heroin more than halved from a peak of 59,000 (37% of first-time treatment entrants) in 2007 to 23,000 (19%) in 2013 before increasing again to 29,000 (21%) in 2015 ([@B11]).

At the same time, in most European countries the number of first-time treatment entrants for primary cannabis use has continuously increased from about 43,000 (28% of all new drug clients) in 2006 to about 75,000 (47% of all new drug clients) in 2015.

Increases have also been reported in the number of first-time treatment entrants for primary amphetamines and methamphetamines use, from approximately 9,000 (6% of all new drug clients) in 2006 to approximately 15,000 (9% of all new drug clients) in 2015, although these were mainly driven by increases in Germany and, to a lesser extent, in the Czech Republic.

Trends in cocaine treatment demands, concentrated in a few countries, show that the overall number of first-time treatment entrants for cocaine declined from a peak of about 35,000 (23%) in 2006 to about 26,000 (17%) in 2015 ([Figure 2](#F2){ref-type="fig"}).

![Trends in percentage of first-time treatment entrants by year and by primary drug 2006--2015. *Notes:* Only countries with at least 9 years of data over the last 10 years were included in the graph. Missing data were interpolated by assigning for the respective country the value for most recent year available. Czech Republic, Malta, and Spain did not report data in 2015; therefore, 2014 data have been used for 2015. Malta did not report data for 2007; therefore, 2006 data have been used for 2007. United Kingdom did not report data for 2012; therefore, 2011 data have been used for 2012. Excluded countries are Belgium, Denmark, Estonia, Lithuania, Luxembourg, Norway, Poland, Portugal, and Sweden.](jsads.2019.s18.139fig2){#F2}

Drug users consuming other substances have recently appeared in drug treatment data in some European countries, such as users of opioids other than heroin (e.g., methadone or buprenorphine misused) or other types of opioid medicines (e.g., tramadol, oxycodone) and some types of NPSs, such as synthetic cannabinoids and cathinones. Between 2006 and 2015, a decline from 28% to 19% of first-time treatment entrants with injection as the main route of administration was reported ([@B11]).

Discussion
==========

According to TDI data, the typical European client entering drug treatment is a man in his 30s, often unemployed, and with unstable living conditions and a low level of education. Among opioid clients, many re-enter drug treatment after one or more previous treatment episodes (70% of opioid clients have been treated before) ([@B13]), and the mean age has increased by 4 years between 2006 and 2015, indicating the presence of an aging cohort of drug users ([@B16]). A history of injecting drug use and poor health, unstable living conditions, and tobacco and alcohol use makes these users susceptible to a range of chronic health and social problems that may accelerate their physical aging and have considerable implications for treatment and social support services ([@B11]).

Women entering treatment make up around one fifth of all entrants to drug treatment in Europe. High male-to-female ratios are reported in the southern European countries and lower ratios in the northern European countries. Women have specific needs that have to be addressed because they are likely to experience stigma and economic disadvantage, have less social support, come from families with substance use problems and have a substance-using partner, have children who may play a central role in their drug use and recovery, have experienced sexual and physical assault and abuse, and have co-occurring mental disorders ([@B12]).

The social profile of clients entering treatment in European countries shows that clients are more socially disadvantaged than the general population,[^13^](#fn13){ref-type="fn"} providing indications for prevention and for addressing social risk factors for drug-related problems.

Concerning drug use patterns, the predominance of primary heroin users entering drug treatment at the beginning of this century in Europe is now replaced by a more diversified treatment client population and by a major increase in demands for cannabis treatment in the last years. An analysis of long-term trends in first heroin treatment demand from 2000 until 2009 showed that the trend peaked in 2007 and then significantly decreased until 2009; the decreasing started earlier in the western European countries and later in the countries of the eastern part of Europe ([@B2]). Factors that could have played a role in the rise of cannabis treatment demands are increases in the prevalence of cannabis use in some countries, in particular intensive cannabis use ([@B22]), treatment availability targeting cannabis use, cannabis market factors (potency and cannabis availability), and changing treatment referral practices (Montanari, 2017).

Drug injection has also substantially decreased in the last 10--15 years. An analysis of TDI data from 2001 until 2011 indicates a decline in injecting drug behavior and its incidence among people admitted to first drug treatment in the 28 EU member states, Norway, and Turkey ([@B23]).

Country differences in patterns of drug use and in client profiles should be considered when describing the European treatment demand data. Clients entering treatment for the use of non-cocaine stimulants are mainly concentrated in the Czech Republic and Slovakia (methamphetamines), and in Bulgaria, Finland, Germany, Hungary, Latvia, and Poland (amphetamines) ([@B17]). The use of cocaine among those demanding treatment is mainly reported in Italy, the Netherlands, Spain, and the United Kingdom (Espelt, 2015); the United Kingdom is the country reporting the most crack cocaine treatment demands in Europe ([@B13]). Furthermore, in Finland, the majority of drug clients seek treatment for problems related to misuse of buprenorphine ([@B1]) and, in Estonia, for problematic use of illicit fentanyl ([@B20]).

Country differences reflect variations in cultural and social factors, extent of drug use and drug use problems in the country, different availability and organization of national treatment programs, drug policies, referral practices, and other possible factors.

Finally, NPSs may pose challenges for users and drug treatment services, but only few persons are reported to enter treatment for the use of NPSs as a primary drug, reflecting low prevalence levels of these substances in the general population, lack of available services, and underreporting.

Limitations
-----------

When describing and interpreting data collected through the TDI in 30 countries across Europe, data limitations should be considered ([@B10]; [@B19]). First, TDI data only represent a part of the drug treatment system, and its level of representativeness may differ by country. Information on the national treatment system and the coverage of the TDI within it are essential prerequisites to understand the context of TDI data collection in each country and how the data coming through the TDI reporting system mirror the actual overall uptake of treatment services in the country. Currently, the data coverage of specialized outpatient and inpatient treatment facilities in most countries is reasonable, whereas for other treatment providers (e.g., general practitioners or low-threshold agencies) the coverage remains low.

Second, national differences in operational definitions limit data comparability. Data are collected according to the same TDI protocol in all reporting countries, based on the same 24 items; however, some differences between countries and within countries in the way data are collected remain. This is particularly the case in countries with a federal organization that gives large autonomy to individual provinces or regions. To interpret the reported data, it is necessary to have a clear understanding of national and subnational details in data collection.

Third, trends should be interpreted with caution, as fluctuations in data reporting, including in the number and type of units reporting data and the number of clients reported, may be influential. Specific analysis of heroin and cannabis trends has been conducted to isolate those factors, but ad hoc analysis is required to better understand the reporting bias.

A fourth limitation is the double counting of individuals. According to the TDI protocol, single individuals are recorded, and not episodes; however, it may happen that a person is registered more than once in a database, which results in an overestimation of the total number of persons entering treatment in a given year. Reasons for double counting include lack of communication between treatment centers and absence of a unique system to allow for crosschecking. Although several techniques exist ([@B21]) and substantial progress has been made in recent years, double counting of cases can only partly be excluded.

A fifth limitation of the indicator is the restricted range of substances included in data collection. As the mandate of the EMCDDA is limited to illicit drugs, the TDI does not collect information on tobacco, and it collects information on alcohol only if it is reported as a secondary drug for entering treatment. Other forms of addiction, such as gambling, are also not included in the TDI.

Furthermore, the TDI only collects information on the client at treatment entrance, and no information is available on the other phases of the treatment process, including treatment exit and outcome. An additional module of the TDI (TDI Prevalence), aiming at collecting data on the number and profile of people who are in continuous treatment (not only entering), was implemented in seven countries in 2015,[^14^](#fn14){ref-type="fn"} with possible expansion in the future.

The last data quality issue is the way data are transmitted from the national to the European level. Treatment monitoring at the EU level is based on the transfer of aggregated data from national sources, which limits the possibilities of the EMCDDA both in terms of quality control and analysis.

To address these issues and improve data quality, a system of data quality assurance has been established. This includes the process of data validation conducted every year, as well as the regular dialogue with the TDI experts nominated in every country. In addition, a detailed system of data quality assessment is conducted every 3 years to scrutinize the data provided by each country for specific criteria of scientific quality and process of TDI implementation at the national level.

Conclusions
-----------

Since its implementation, the TDI has become the largest drug-related data set in Europe, and it is used in various analyses of the drug situation and trends. The use of a common data collection tool across countries represents a powerful instrument for policymakers at the European level and allows drug professionals to compare their national situation in drug treatment and drug problems with other countries in order to improve their national responses. Data collected in 30 countries through the TDI remain the main information source on the extent and patterns of drug problems and sociodemographics of individuals experiencing drug problems and in contact with treatment services in the EU member states, Norway, and Turkey.

The success of the TDI in monitoring the drug situation in Europe over the last 20 years is the fruit of a collaborative effort between the EMCDDA and its network of national experts. Further efforts will be required for the TDI to reflect and adapt to fast-paced changes in the drug markets (e.g., NPSs) and a greater diversification of health care systems (e.g., increased importance of e-health).
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The other four indicators are (a) extent and pattern of drug use in the general population, (b) prevalence of problem drug use, (c) drug-related deaths and mortality of drug users, and (d) drug-related infectious diseases.

See later in the text for a description of the EMCDDA.

<http://www.coe.int/T/dg3/pompidou>

<http://www.emcdda.europa.eu/publications/manuals/tdi-protocol-3.0>

On January 1, 2018, the 28 European member states were as follows: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom.

In the current data reporting tool (FONTE) through which the countries report aggregated data to the EMCDDA, only two secondary drugs can be indicated.

Countries included were Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, United Kingdom, Norway, and Turkey. Sweden was not included in data reported because most definitions were not in line with the EMCDDA definitions. Norway is not included in the analysis on first-time treatment entrants because data were not available.

\(a\) The unemployment rate was 4.4% in Norway and 10.3% in Turkey. See: <http://ec.europa.eu/eurostat/statistics-explained/index.php/Unemployment_statistics>.

\(b\) Housing conditions statistics can be found at <http://ec.europa.eu/eurostat/statistics-explained/index.php/People_in_the_EU_%E2%80%93_statistics_on_housing_conditions#Severe_housing_deprivation>.

\(c\) The educational level can be found at <http://ec.europa.eu/eurostat/statistics-explained/index.php/Glossary:Early_leaver_from_education_and_training>.

NPSs are defined as new narcotic drugs or new psychotropic drugs in pure form or in a preparation that have not been listed under the 1961 United Nations Single Convention on Narcotic Drugs (Schedule I, II, or IV) or under the 1971 United Nations Convention on Psychotropic Substances (Schedule I, II, III, or IV).

For the following countries, last available data refer to 2014: Bulgaria, Czech Republic, Denmark, Hungary, and Spain.

France, Germany, Italy, Latvia, Malta, the Netherlands, Romania, Slovakia, Turkey, and the United Kingdom.

France, Germany, Latvia, the Netherlands, Romania, and Slovakia.

The unemployment rate was 4.4% in Norway and 10.3% in Turkey. See: <http://ec.europa.eu/eurostat/statistics-explained/index.php/Unemployment_statistics>. Housing conditions statistics can be found at <http://ec.europa.eu/eurostat/statistics-explained/index.php/People_in_the_EU_%E2%80%93_statistics_on_housing_conditions#Severe_housing_deprivation>; educational level: <http://ec.europa.eu/eurostat/statistics-explained/index.php/Glossary:Early_leaver_from_education_and_training>.

In 2015, seven countries have reported data on TDI Prevalence. They were Cyprus, Finland, France, Latvia, the Netherlands, Romania, and the United Kingdom.
